The status of our initial lentiviral-based gene therapy programs is reflected below. 8226; Restoration of protein function. We also are in the process of establishing a CMO partnership in Europe. This concept is illustrated in the graphs below. The remainder of the AEs were Grade 2 or Grade 1. 11 As of March 1, 2021, five patients have been dosed in the FAB-GT clinical trial. Bruising, risk of bleeding and fatigue are common due to the thrombocytopenia and anemia. The baseline measurement was taken one month prior to discontinuation of ERT. Intellectual property licensed to us under this agreement relates to our Fabry program. We may terminate the agreement for any reason upon notice to BioMarin. The market for treatment of lysosomal disorders is especially large and competitive. After a BLA is approved, the product also may be subject to official lot release. This amendment to the PHS Act attempts to minimize 34 duplicative testing. 41 Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. As of December 31, 2020, we had cash and cash equivalents of $259.7 million. As of March 1, 2021, we have dosed only 14 patients across four ongoing clinical trials. A failure of one or more clinical studies can occur at any stage of testing. Designation as a breakthrough therapy is within the discretion of the FDA. There is no assurance we will not experience lot failures in the future. There are, in general, relatively few alternative sources of supply for these components. We are in the preliminary stages of building our commercial organization. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Additionally, HHS, has already implemented certain measures. We cannot predict the initiatives that may be adopted in the future. We can face serious consequences for violations. Our operations also produce hazardous waste products. We may have experienced ownership changes in the past. Any such dispute could have a material adverse effect on our business. Many of our product candidates are in-licensed from third parties. We may not be able to protect our intellectual property rights throughout the world. A patent may only be extended once and only based on a single approved product. An active trading market for our common stock may not be sustained.